People who carry a specific mutation in the gene for a small protein called SHLP2 are about half as likely to develop Parkinson’s disease, a study from the University of Southern California (USC) has found, offering a new direction to treat the disease. The mutation, found mainly in people…
Scientists have uncovered the complex structure and interplay of two proteins, called LRRK2 and Rab29, that are implicated in late-onset Parkinson’s disease. Specifically, they found LRRK2 is recruited to the membranes of cells by forming a complex with Rab29, causing LRRK2 to undergo changes in its structure and adopting…
A man with Parkinson’s disease saw an easing of his motor and nonmotor symptoms and better fitness after taking part in Spinning Wheels, an 85-day, cross-country bike tour of Canada supporting people with the neurodegenerative condition. Steve Iseman, 57, cycled 7,850 km (nearly 5,000 miles) from Canada’s west…
A protein called NEMO can dock to misfolded forms of alpha-synuclein — the protein whose toxic aggregates damage and kill nerve cells in Parkinson’s disease — sending them off for recycling in cellular structures called lysosomes, a study reports. But problems with this waste disposal process can lead to…
Alpha-synuclein, the protein that builds up into toxic clumps in Parkinson’s disease, may trigger neurons (nerve cells) to increase their production of new proteins, ultimately causing them to die, according to a recent study. “Parkinson’s disease has major impacts on quality of life for patients, but also for their…
Factors such as exposure to environmental toxins and repeated blows to the head — all of which can be reduced with prevention efforts — may account for nearly 1 in 3 cases of Parkinson’s disease among men, and 1 in 4 among women. That’s according to a study of…
Alpha-synuclein — the protein that forms toxic clumps in the brains of people with Parkinson’s disease — may travel from enteroendocrine cells lining the gut to the brain through the vagus nerve, according to a study aiming to build on previous evidence of a gut-brain axis in Parkinson’s.
A ceramic blanket, a device being developed by Gladiator Therapeutics to improve blood flow and speed up wound healing, improved motor performance in a mouse model of Parkinson’s disease in a recent study. Besides improving balance and movement, the blanket also resulted in an increased number of cells…
Vanqua Bio will initiate clinical development of VQ-101 — a small molecule capable of penetrating the brain — in the first quarter of 2024, the company announced. The clinical testing will involve both healthy volunteers and individuals with Parkinson’s disease associated with mutations in the GBA gene.
Low-dose fosgonimeton (ATH-1017), an investigational small molecule, may have cognitive benefits for people with Parkinson’s disease-related dementia or dementia with Lewy bodies, according to recent data from a clinical trial. The small exploratory Phase 2 study, called SHAPE (NCT04831281), tested the safety and efficacy of fosgonimeton given once…
Get regular updates to your inbox.
